Kelly Warfield - Emergent Biosolutions Senior Development
| EBS Stock | USD 1.92 0.03 1.54% |
Executive
Kelly Warfield is Senior Development of Emergent Biosolutions
| Address | 400 Professional Drive, Gaithersburg, MD, United States, 20879 |
| Phone | 240 631 3200 |
| Web | https://www.emergentbiosolutions.com |
Emergent Biosolutions Management Efficiency
The company has Return on Asset of (0.048) % which means that on every $100 spent on assets, it lost $0.048. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.7467) %, meaning that it generated no profit with money invested by stockholders. Emergent Biosolutions' management efficiency ratios could be used to measure how well Emergent Biosolutions manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to gain to -0.57 in 2024. Return On Capital Employed is likely to gain to -0.14 in 2024. At this time, Emergent Biosolutions' Total Assets are comparatively stable compared to the past year. Non Current Assets Total is likely to gain to about 2.4 B in 2024, whereas Deferred Long Term Asset Charges is likely to drop slightly above 9 M in 2024.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Michael Guptan | Walmart | N/A | |
| Michael Duran | 3M Company | N/A | |
| Jamie Engstrom | Caterpillar | N/A | |
| Ahmed Badri | Cisco Systems | N/A | |
| Marie Myers | HP Inc | 56 | |
| Timothy Brown | HP Inc | 57 | |
| Deborah Majoras | Procter Gamble | 57 | |
| Geoffrey Greener | Bank of America | 59 | |
| Fletcher Previn | Cisco Systems | N/A | |
| Matthew Janzaruk | Procter Gamble | 50 | |
| Mark II | 3M Company | 56 | |
| Jeffery Sharritts | Cisco Systems | 55 | |
| Javier Polit | Procter Gamble | N/A | |
| David Rozzion | HP Inc | N/A | |
| Chandrakant Patel | HP Inc | N/A | |
| Vittorio Cretella | Procter Gamble | N/A | |
| Maria Poveromo | Cisco Systems | N/A | |
| Suzette Long | Caterpillar | 58 | |
| Jananne Copeland | Caterpillar | 54 | |
| Gillian McDonald | McDonalds | 58 | |
| Luigi Faltoni | 3M Company | N/A | |
Management Performance
| Return On Equity | -0.75 | ||||
| Return On Asset | -0.048 |
Emergent Biosolutions Leadership Team
Elected by the shareholders, the Emergent Biosolutions' board of directors comprises two types of representatives: Emergent Biosolutions inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Emergent. The board's role is to monitor Emergent Biosolutions' management team and ensure that shareholders' interests are well served. Emergent Biosolutions' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Emergent Biosolutions' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Kelly Warfield, Senior Development | ||
| Sean Kirk, Executive Vice President - Manufacturing and Technical Operations | ||
| William Hartzel, Senior Bioservices | ||
| Robert Burrows, IR Contact Officer | ||
| Stephanie Duatschek, Chief VP | ||
| Sue Bailey, Independent Director | ||
| Jerome Hauer, Independent Director | ||
| Haywood Miller, Interim Officer | ||
| Kathryn Zoon, Independent Director | ||
| Seamus Mulligan, Director | ||
| George Joulwan, Independent Director | ||
| Karen Smith, Executive Vice President Chief Medical Officer | ||
| Paul Williams, Senior Business | ||
| Daniel AbdunNabi, President CEO, Director | ||
| Keith Katkin, Independent Director | ||
| Robert Kramer, CFO, Interim Executive Vice President - Corporate Services Division, Principal Financial and Accounting Officer, Treasurer | ||
| Richard MBA, CFO VP | ||
| Jennifer Fox, Executive Vice President - External Affairs, General Counsel, Corporate Secretary | ||
| Katherine Strei, Executive Vice President - Human Resources and Communications, Chief Human Resources Officer | ||
| Michelle Pepin, Senior Officer | ||
| Fuad ElHibri, Executive Chairman of the Board | ||
| Coleen Glessner, Executive Compliance | ||
| Lynn Kieffer, VP Communications | ||
| Joseph Papa, CEO President | ||
| Marvin White, Director | ||
| Atul Saran, Executive Vice President Corporate Development, General Counsel and Corporate Secretary | ||
| Robert Sr, Pres CEO | ||
| Adam Havey, Executive VP and President of Biodefense Division | ||
| Louis Sullivan, Independent Director | ||
| Ronald Richard, Lead Independent Director | ||
| Zsolt Harsanyi, Non-Executive Independent Chairman of the Board | ||
| Richard Lindahl, Chief Financial Officer, Executive Vice President, Treasurer |
Emergent Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Emergent Biosolutions a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.75 | ||||
| Return On Asset | -0.048 | ||||
| Profit Margin | (0.72) % | ||||
| Operating Margin | (0.18) % | ||||
| Current Valuation | 866.03 M | ||||
| Shares Outstanding | 52.39 M | ||||
| Shares Owned By Insiders | 1.88 % | ||||
| Shares Owned By Institutions | 78.65 % | ||||
| Number Of Shares Shorted | 5.89 M | ||||
| Price To Earning | 1.67 X |
Emergent Biosolutions Investors Sentiment
The influence of Emergent Biosolutions' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Emergent. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Emergent Biosolutions' public news can be used to forecast risks associated with an investment in Emergent. The trend in average sentiment can be used to explain how an investor holding Emergent can time the market purely based on public headlines and social activities around Emergent Biosolutions. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Emergent Biosolutions' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Emergent Biosolutions' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Emergent Biosolutions' news discussions. The higher the estimated score, the more favorable is the investor's outlook on Emergent Biosolutions.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Emergent Biosolutions in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Emergent Biosolutions' short interest history, or implied volatility extrapolated from Emergent Biosolutions options trading.
Pair Trading with Emergent Biosolutions
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Emergent Biosolutions position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Emergent Biosolutions will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Emergent Biosolutions could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Emergent Biosolutions when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Emergent Biosolutions - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Emergent Biosolutions to buy it.
The correlation of Emergent Biosolutions is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Emergent Biosolutions moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Emergent Biosolutions moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Emergent Biosolutions can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Emergent Biosolutions. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics. For more information on how to buy Emergent Stock please use our How to Invest in Emergent Biosolutions guide.Note that the Emergent Biosolutions information on this page should be used as a complementary analysis to other Emergent Biosolutions' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Complementary Tools for Emergent Stock analysis
When running Emergent Biosolutions' price analysis, check to measure Emergent Biosolutions' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Emergent Biosolutions is operating at the current time. Most of Emergent Biosolutions' value examination focuses on studying past and present price action to predict the probability of Emergent Biosolutions' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Emergent Biosolutions' price. Additionally, you may evaluate how the addition of Emergent Biosolutions to your portfolios can decrease your overall portfolio volatility.
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities |
Is Emergent Biosolutions' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Emergent Biosolutions. If investors know Emergent will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Emergent Biosolutions listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.022 | Earnings Share (14.85) | Revenue Per Share 20.494 | Quarterly Revenue Growth (0.16) | Return On Assets (0.05) |
The market value of Emergent Biosolutions is measured differently than its book value, which is the value of Emergent that is recorded on the company's balance sheet. Investors also form their own opinion of Emergent Biosolutions' value that differs from its market value or its book value, called intrinsic value, which is Emergent Biosolutions' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Emergent Biosolutions' market value can be influenced by many factors that don't directly affect Emergent Biosolutions' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Emergent Biosolutions' value and its price as these two are different measures arrived at by different means. Investors typically determine if Emergent Biosolutions is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Emergent Biosolutions' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.